Do Price Subsidies on Artemisinin Combination Therapy for Malaria Increase Household Use?: Evidence from a Repeated Cross-Sectional Study in Remote Regions of Tanzania

摘要: The Affordable Medicines Facility-malaria (AMFm) is a pilot program that uses price subsidies to increase access Artemisinin Combination Therapies (ACTs), currently the most effective malaria treatment. Recent evidence suggests availability and affordability of ACTs in retail sector drug shops (where many people treat malaria) has increased under AMFm, but it unclear whether household level ACT use increased. HOUSEHOLD SURVEYS WERE CONDUCTED IN TWO REMOTE REGIONS OF TANZANIA (MTWARA AND RUKWA) THREE WAVES: March 2011, December 2011 2012, corresponding 3, 13 16 months into AMFm implementation respectively. Information about suspected episodes including treatment location medications taken was collected. Respondents were also asked antimalarial preferences perceptions these medications. Significant increases use, preference perceived found between Rounds 1 3 though not for all measures 2. among 51.1% by 10.9 percentage points Round (p = .017). greatest patients, where from 31% 49% 2 (p = .037) 61% (p<.0001) 3. fraction treated 30.2% 46.7% (p = .0009), mostly due decrease patients who sought no at all. No significant changes public seeking found. led malaria, especially sector. supporting concerns would crowd out or neglect remote areas low SES groups.